Delivra Strengthens Board for USA Product Launches

TORONTO, ON--(Marketwired - April 18, 2016) - Delivra Corp. (TSX VENTURE: DVA) ("Delivra" or the "Company") is pleased to announce the appointment of Mr. David T. Thibodeau to its Board of Directors.

As Managing Director of Boston-based Wellvest Capital, Mr. Thibodeau is a seasoned corporate finance executive within the wellness industry, with a successful history of entrepreneurship, corporate strategy, growth management, capital markets, and mergers & acquisitions. He was an early player in the consumer health and wellness sector, where he has developed a particular expertise over the last 25+ years. Prior to Wellvest Capital, David spent 10 years at the investment bank Canaccord Genuity (formerly Adams, Harkness and Hill). As the head of the Health, Wellness and Lifestyle corporate finance group, he focused on mergers, acquisitions, public and private financings. David led the evolution of the firm's Healthy Living practice into the broader and more robust Health, Wellness and Lifestyle sector. Over that time, David was an advisor on many of the industry's leading and transformative M&A transactions that have helped define the evolution of the emerging wellness industry. Examples of these transactions include ZonePerfect Nutrition and EAS sale to Abbott Laboratories, Metagenics joint venture with Alticor, Martek Bioscience's purchase of Amerifit Nutrition, Garden of Life's sale to Atrium Innovations, SunPure's sale to Kerry Group PLC, Pure World's sale to Naturex SA, and Imagine Foods sale to Hain Celestial Group.

"I am excited to have the opportunity to join the Delivra board at this transformative time, as it looks to extend the market reach of its best-in-class products beyond Canada and into the United States," said Mr. Thibodeau. "I look forward to contributing to Delivra's continued success by leveraging my many years of consumer health and wellness experience in US and international markets."

Internally, Delivra now has its US leadership team in place, and its progress continues on strategy and implementation for market entry and growth, beginning with a robust digital initiative and followed by a strong retail program.

"Building on the solid growth of our LivRelief™ products in Canada, and the recent foundational investments in infrastructure and operations, our major current growth initiative within our consumer healthcare products business is the penetration of the vast US market," said Dr. Joseph Gabriele, Chairman and CEO of Delivra. "We are very pleased to have a professional with the tremendous experience and expertise of Mr. Thibodeau join our team, and we are confident that he will make a strong contribution to our continued success."

ABOUT DELIVRA CORP.

Delivra Corp. is a developer of transdermal technologies for the delivery of pharmaceutical and natural molecules through the skin, rather than via pills. Delivra manufactures and sells a growing line of natural topical creams under the LivRelief™ brand, for conditions such as joint and muscle pain, nerve pain, varicose veins, wound healing, and sports performance. LivRelief™ products are available in pharmacies, grocery chains, and independent health food stores across Canada, and on-line at www.livrelief.com. In parallel with its consumer products business, Delivra also has a mandate to license its unique, proven, and patent-pending delivery platform to global pharmaceutical companies for the transdermal delivery of third party active ingredients to treat a broad range of conditions. Delivra is headquartered in Burlington, Ontario and has a research and development laboratory in Charlottetown, PEI.

The TSX Venture Exchange has neither approved nor disapproved the contents of this press release. Neither the Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.

Certain information in this press release may constitute forward-looking information. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict. Actual results might differ materially from results suggested in any forward-looking statements. The Corporation assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward looking-statements unless and until required by securities laws applicable to the Corporation. Additional information identifying risks and uncertainties is contained in the Corporation's filings with the Canadian securities regulators, which filings are available at www.sedar.com.